GEN Exclusives

More »

GEN Poll

More »
Jun 13, 2013

Myriad Genetics Trial: Your Thoughts?

The U.S. Supreme Court just delivered a mixed decision for companies looking to patent human genes, ruling against Myriad Genetics’ patent claims for breast cancer susceptibility genes BRCA 1 and 2, but also holding that companies can patent composite DNA (cDNA) and other synthetic genetic material that does not meet the “product of nature” exemption from patentability. How do you feel about this?

Do you agree with the Supreme Court’s decision in the Myriad case?


Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »